ESMO Events 2026
Meetingsopens in new tab/window | ESMOopens in new tab/window
Welcome to our ESMO Virtual Congress site where we showcase the very best from ESMO's flagship portfolio.
Below two collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of each meeting:
ESMO Targeted Anticancer Therapies Asia Congress 2026opens in new tab/window
We are delighted to welcome you to the second edition of the ESMO Targeted Anticancer Therapies Asia Congress, taking place from 12 to 14 June 2026 in Hong Kong SAR, China. Building on the success of our inaugural event, this congress continues to serve as a key platform in the Asia-Pacific region for showcasing the latest advances in early-phase drug development and precision oncology.
Designed for researchers, clinicians, and industry professionals at the forefront of innovation, ESMO TAT Asia 2026 offers an exceptional opportunity to explore cutting-edge science, foster cross-disciplinary collaboration, and accelerate the translation of novel therapies into clinical practice. Join us as we bring together global experts and regional leaders to shape the future of targeted anticancer treatment.
Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of the meeting.
Annals of Oncology
Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 studyopens in new tab/window R.J. Motzer, L. Albiges, S.A. Treviño Aguirre, R. Kanesvaran, P. Centkowski, M.A. Reimers, J.P. Sade, D. Pouessel, E. Biscaldi, E. Esteban, J.Á. Arranz Arija, S.S. Tykodi, M. van Kooten Losio, A. Dighe, H. Ma, V. Valmeekam, A. Simmons, C. Scheffold, S. Andrianova, D.A. Braun, T. Powles, T.K. Choueiri
Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trialopens in new tab/window R. Liu, J. Zhao, R. Zhang, B. Liu, Y. Liu, S. Li, Y. Chen, H. Yang, Z. Liu, Z. Li, Y. Qin, M. Huang, Y. Ba, H. Zhang, Y. Qu, Y. Du, T. Deng, M. Yang, X. Hou, C. Liu, F. Ning, Y.P. Liu, X. Wu, Y. Xie, Y. An, K. Zou, L. She, J. Xu
ESMO Open
Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib–fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast canceropens in new tab/window S.-A. Im, K. Kalinsky, K.L. Jhaveri, S. Loibl, N. Turner, C. Saura, P. Schmid, S. Loi, E. Hamilton, N. Karadurmus, S. Wang, A.A. Awan, E.M. Ciruelos, C.-F. Chung, E. Thanopoulou, N. Shankar, S. Lim, Y. Jin, C. Song, D. Juric
Efficacy of olaparib in advanced cancers with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2opens in new tab/window S. Joris, H. Denys, J. Collignon, M. Rasschaert, D.T. de Roodenbeke, F.P. Duhoux, J.L. Canon, S. Tejpar, J. Mebis, L. Decoster, P. Aftimos, J. De Grève
Immuno-Oncology and Technology
Safety and feasibility of blood-derived multiple antigen-specific endogenously derived T cells (MASE-T) for metastatic melanomaopens in new tab/window T.J. Monberg, S.A. Tvingsholm, M. Svensson-Frej, C. Vestergaard, M. Ormhøj, J.W. Kjeldsen, T.H. Borch, R.B. Holmstroem, N. Jayashankar, J.S. Granhøj, A.R. Cordt, S.K. Larsen, Ö. Met, S.R. Hadrup, I.M. Svane
ESMO Gastrointestinal Oncology
Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal canceropens in new tab/window M. Fakih, S. Gill, K. Sampat, D.L. Chan, G. Fisher, M. Cruz-Correa, H.-J. Lenz, P. Garcia-Alfonso, F. Forget, S. Lonardi, J. Krauss, E. Chen, A. Cubillo Gracian, Y. Liu, N. van Buuren, J. Shao, M. Dong, A. Chen, M. Tejani, J.R. Hecht
ENVELOPE: enfortumab vedotin in patients with advanced small bowel adenocarcinoma refractory or intolerant to platinum-based therapy—phase II investigator-initiated trial (NCCH2412/MK015)opens in new tab/window H. Fujii, H. Hirano, T. Kudo, K. Tsuchihashi, H. Shoji, N. Okita, T. Hirose, A. Takashima, M. Yokoyama, M. Kawasaki, Y. Shuda, M. Naito, K. Ichikawa, K. Sekine, J. Sato, N. Yamamoto, K. Kato
ESMO Real World Data and Digital Oncology
Evolving phase I oncology trials in the precision medicine era: design, outcomes, and geographic accessopens in new tab/window Y. Katsuya, T. Koyama, J. Sato, M. Okada, N. Yamamoto
How artificial intelligence applied to digital pathology could guide treatment personalization in breast canceropens in new tab/window T. Ruelle, T. Grinda, L. Del Mastro, M. Lacroix-Triki, B. Pistilli, G. Gessain
ESMO Rare Cancers
Disulfiram and copper radiosensitizes chordoma by targeting chordoma cancer stem cells and senescent cellsopens in new tab/window F. Chen, L. Liu, E. Choy, E. Wang, A. Sadagopan, Y.-L.E. Chen, D. Wang, J. Yang, N. Kizielewicz, L. Yu, J.H. Schwab, D.G. Tobert, X. Wang
Initial experience with perioperative immune checkpoint inhibitors combined with radiotherapy for head and neck mucosal melanoma: a case seriesopens in new tab/window S. Hiraoka, R. Nakashima, M. Nomura, H. Ito, M. Yoshimura, K. Honda, Y. Kishimoto, T. Mizowaki, K. Omori
ESMO affiliated journals
Impact of trastuzumab deruxtecan (T-DXd) and brain stereotactic radiosurgery on intracranial control and radionecrosis risk in HER2-positive or -low breast cancer brain metastasesopens in new tab/window Seok-Joo Chun, Kyubo Kim, Won Ick Chang, Yong Bae Kim, Sun Ha Paek, Kyung-Hun Lee, Jin-Ho Song, Ji Hyun Hong, Jieun Lee, Won Il Jang, Tae Hyun Kim, Kyung Hwan Shin
Antibody–drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposureopens in new tab/window Fatih Kemika, Taha Koray Şahin, Hakan Özçelik, Ahmet Sezer, Gül Başaran, Sakine Damla Açıkel Yüksel, Gizem Güney, İbrahim Yıldız, Özlem Er, Taner Korkmaz, Sedat Biter, Dilek Erdem, Salih Tünbekici, Ahmet Oruç, Ali Kaan Güren, Kerim Kaban, Musa Barış Aykan, Ömer Burak Ekinci, İlknur Deliktaş Onur, Ali Kalem, Oğuz Altunok, Mustafa Seyyar, Bünyamin Güney, Orhun Akdoğan, Melike Yazıcı, Nargiz Majidova, Sema Türker, Bahadır Köylü, Cevat İlteriş Kıkılı, Nazan Demir, Didem Tunalı, Şahin Laçin, Deniz Tural, Ahmet Bilici, Ertuğrul Bayram, Erdem Göker, Murat Araz, İbrahim Vedat Bayoğlu, Nil Molinas Mandel, Nuri Karadurmuş, Emir Çelik, Öztürk Ateş, Havva Yeşil Çınkır, Mesut Yılmaz, Rıza Umar Gürsu, Ozan Yazıcı, Devrim Çabuk, Deniz Can Güven, Fatih Selçukbiricik, Sercan Aksoy, Şeyda Gündüz
Integrin beta-6: Its emerging role as a therapeutic target in solid tumorsopens in new tab/window Rachel E. Sanborn, Solange Peters, David Barbie
Immunotherapy with anti-PD-1 or PD-L1 in advanced ovarian cancer: A meta-analysis of randomized trialsopens in new tab/window Riccardo Vida, Michele Bartoletti, Marcella Montico, Sandro Pignata, Gustavo Baldassarre, Antonino Ditto, Giulia Zapelloni, Monica Rizzetto, Ludovica Lay, Poletto Margherita, Fabio Puglisi
Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung canceropens in new tab/window Ross A. Soo, Pablo Fernandez-Penas, Molly Li, Pei Jye Voon, Junko Tanizaki, Jeng-Sen Tseng, Chris Tan, Xiao Rong Dong, Kumar Prabhash, Hye Ryun Kim, Kazuo Hasegawa, Nicole Parkinson, Julian Kam, Jairo Simoes, Marija McGeachie, Shun Lu, Nick Pavlakis
Comparative efficacy of tarlatamab and second-line therapies in extensive-stage small cell lung cancer: a network meta-analysisopens in new tab/window Jessie Wang, Rumbidzai Takundwa, Hongbo Yang, Xinglei Chai, Youfei Yu, Yuehan Zhang, Franziska Dirnberger, Erik S. Anderson, Malaika Pastel, Xerxes Pundole, Igor Gomez-Randulfe, Fiona Blackhall
FORTRESS-CART: Focused Observation and Risk Testing for Robust Evaluation of Safety in Chimeric Antigen Receptor T-Cell Therapy (CAR-T): Real-World Predictors of Second Primary Malignancies (SPMs) Among Patients Treated With CAR-Topens in new tab/window Rafael Fonseca, Surbhi Sidana, Kevin C. De Braganca, Tamar Lengil, Ahmed Mohamed, Helen Pai, Matthew Perciavalle, Bruno Emond, Todd Bixby, Zaina P. Qureshi, Peter Voorhees
Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor–Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1opens in new tab/window Francesca Palandri, Nicolaas P.M. Schaap, Jerome Rey, Nikolas von Bubnoff, Andreas Reiter, Juan Carlos Hernandez-Boluda, Timothy Devos, Lars Nilsson, Bethan Psaila, Donal P. McLornan, Bryan Strouse, Shiyuan Zhang, Bharat Patel, Jessica Lim, Dwaipayan Patnaik, Stephen T. Oh
ESMO Gynaecological Cancers Congress 2026opens in new tab/window
This conference is dedicated to advancing our understanding and treatment of gynaecological cancers, including ovarian, cervical, uterine, vaginal, and vulvar malignancies. Bringing together leading experts, researchers, and healthcare professionals from around the world, the programme features keynote lectures, dynamic discussions, and interactive sessions designed to foster collaboration and accelerate progress in the field.
A special focus is aimed at supporting the next generation of oncology professionals. Young specialists have the opportunity to present their work, gain recognition, and establish valuable mentorships with renowned leaders in gynaecological oncology.
Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of the meeting.
Annals of Oncology
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian canceropens in new tab/window P. Harter, F. Trillsch, A. Okamoto, A. Reuss, J.-W. Kim, M.J. Rubio-Pérez, M.A. Vardar, G. Scambia, O. Trédan, G.-B. Nyvang, N. Colombo, M. Bidziński, C. Grimm, S. Lheureux, E. Van Nieuwenhuysen, F. Heitz, R.M. Wenham, S. Nishio, M.C. Lim, G. Marquina, Ö. Altundağ, A. Bergamini, R. Sabatier, P. Wimberger, M.A. Gold, J. Sehouli, T.-W. Park-Simon, E. Kent, A. Correa, C. Aghajanian, on behalf of the DUO-O Investigators
Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008opens in new tab/window S.Y. Ryu, W. Deng, K. Albuquerque, W.-J. Koh, J. Mayadev, A. Heugel, B.-J. Kim, D.-Y. Kim, C.-H. Cho, J.-W. Kim, J.H. No, R.S. Mannel, K. Miller, D. Fabian, D.M. Chase, K.M. Gil, W. Small, Jr., W. Rodgers, C.A. Leath, III, B.J. Monk
ESMO Open
A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) studyopens in new tab/window S.Y. Ryu, B.H. Nam, M.H. Kim, W.I. Jang, C. Sitathanee, T.D. Linh, K.H. Lee, W.M. Lee, E.T. Kim, S.B. Kang, J.H. Kim, J.Y. Park, K.B. Lee, C.H. Cho, H. Lou, Y.H. Kim, Y.T. Kim, Y.H. Lee, X. Wu, J.W. Kim, S.I. Park, S. Jeon, D.H. Thinh, S.F. Kry, D. Gaffney, W. Small, S. Wilailak
Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trialopens in new tab/window L. Paracchini, A. Velle, P. Di Gennaro, L. Mannarino, L. Ancona, D. Lorusso, S.C. Cecere, N. Colombo, L. Beltrame, A. Fagotti, G. Tasca, M. Piemontese, L. Arenare, D. Califano, F. Galdiero, R. Zadro, P. Chiodini, F. Perrone, E. Biagioli, M. D’Incalci, C. Romualdi, S. Pignata, S. Marchini
Immuno-Oncology and Technology
Safety of intratumoral immunostimulatory LOAd703 gene therapy combined with chemotherapy in patients with advanced canceropens in new tab/window A. Hahn, S. Irenaeus, L.C. Sandin, J. Wenthe, E. Eriksson, J.L. Jarblad, A. Schiza, H. Dahlstrand, U. Olsson-Strömberg, J. Krause, A. Sundin, A. Loskog, G.J. Ullenhag
ESMO Real World Data and Digital Oncology
Ovarian cancer recurrence prediction: comparing confirmatory to real-world predictors with machine learningopens in new tab/window D. Katsimpokis, A.E.C. van Odenhoven, M.A.J.M. van Erp, H.H.B. Wenzel, M.A. van der Aa, M.M.H. van Swieten, H.P.M. Smedts, J.M.J. Piek
Real-world outcomes following PARP inhibitor maintenance in ovarian cancer by BRCA status: a retrospective cohort studyopens in new tab/window K. Zucker, B. Pickwell-Smith, A. Samani, A. Sujenthiran, H. Pittell, P. Mpofu, G. Hall
ESMO Rare Cancers
Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy in patients with inadvertently morcellated uterine leiomyosarcomaopens in new tab/window Y.-T. Lai, Y.-N. Lu, D. Xie, M. Gao, Y.-C. Xing, M.-Q. Feng, W.-H. Lu, X.-J. Guo, Y.-F. Ye, M.-M. Guan, M.-L. Huang, M.-F. Wu, Z.-Q. Lin, B.-Z. Zhang, D.-Y. Wang, J. Li
ESMO affiliated journals
Immunotherapy with anti-PD-1 or PD-L1 in advanced ovarian cancer: A meta-analysis of randomized trialsopens in new tab/window Riccardo Vida, Michele Bartoletti, Marcella Montico, Sandro Pignata, Gustavo Baldassarre, Antonino Ditto, Giulia Zapelloni, Monica Rizzetto, Ludovica Lay, Poletto Margherita, Fabio Puglisi
ESMO's Journal Portfolio
While diverse in nature and in content, these journals offer ESMO members and the oncology community a highly visible platform to publish important scientific studies, and a highly credible source for educational updates. Elsevier is the proud publisher of Annals of Oncology, Immuno-Oncology and Technology (IOTECH), ESMO Open, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology, ESMO Rare Cancers, and ESMO Affiliated Journals The Breast, Lung Cancer, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia.
